As per our research report, the size of the Latin American generic drugs market was valued at USD 37.14 billion in 2023 and is predicted to be worth USD 53.92 billion by 2029 from USD 39.52 billion in 2024, growing at a CAGR of 6.41% during the forecast period.
The pharmaceutical industry plays a vital role in the growth of generic drugs. The primary driver of the Latin American generic drugs market is patent expiration which helps initial developer produce lower-cost generic variants and introduce them into the market. Generic drugs are of the same quality. There may be some changes in flavor, size, and color, but they act the same as the branded drugs. Dosing, safety, strength, quality, how it operates, how it is taken, and how it should be utilized are all the same as the branded drugs.
People prefer most generic drugs as they are cost-efficient and affordable. In addition, an increase in the rates of rising chronic illness is boosting the sales of generic, advances in the formulation of the drugs, and market players are also driving the market growth.
However, patient preferences and assumptions are less likely to choose generic drugs because they believe generic therapies are inferior to branded treatments. Doctors rarely prescribe generic drugs, and chemists only supply medicines that are written on the prescription. In addition, the FDA’s strict guidelines and rules for the approval and side effects of the drugs due to some variation during formulation, color, or flavor are restraining the market growth. Doctor preference towards brands and their brand loyalty towards the branded drugs. Also, generic drugs are not possible as they take a long time to expire any patent.
Based on region, Brazil has the highest CAGR in this region. On the other hand, Mexico is estimated to experience strong growth in the generic drug market in the coming future. Also, it is expected to increase the demand with supportive industry and government initiatives; the market is expected to expand the growth of generic medicine during the forecast period.
Companies playing a noteworthy role in the Latin America generic drugs market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd. and Teva Pharmaceuticals.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region